Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare, highly aggressive cancer, often insensitive to conventional chemotherapeutics agents. Early diagnosis, followed by radical surgical resection plus/minus adjuvant mitotane therapy, is nowadays the only valuable option. Unfortunately, one out of four patients...
Main Authors: | Chiara Fiorentini, Salvatore Grisanti, Deborah Cosentini, Andrea Abate, Elisa Rossini, Alfredo Berruti, Sandra Sigala |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2019/6072863 |
Similar Items
-
Immunotherapy failure in adrenocortical cancer: where next?
by: Deborah Cosentini, et al.
Published: (2018-11-01) -
Adrenocortical Carcinoma
by: Alfredo Berruti, et al.
Published: (2021-03-01) -
Cytotoxic Effect of Trabectedin In Human Adrenocortical Carcinoma Cell Lines and Primary Cells
by: Andrea Abate, et al.
Published: (2020-04-01) -
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
by: Deborah Cosentini, et al.
Published: (2021-04-01) -
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
by: Salvatore Grisanti, et al.
Published: (2021-02-01)